These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 6447832)
1. [Chemotherapy of pancreatic cancer is not yet generally recommended]. Hartwich G Med Klin; 1980 Aug; 75(16):575-9. PubMed ID: 6447832 [No Abstract] [Full Text] [Related]
2. Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer. Smith FP; Rustgi VK; Schertz G; Woolley PV; Schein PS Cancer Treat Rep; 1982 Dec; 66(12):2095-6. PubMed ID: 6215982 [No Abstract] [Full Text] [Related]
3. [Chemotherapy of pancreatic cancer]. Yoshimori M; Tajiri H; Nakamura K; Ozaki H Gan To Kagaku Ryoho; 1985 Feb; 12(2):227-34. PubMed ID: 3155930 [TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy for advanced pancreatic carcinoma]. Yokoyama T; Shimada Y Gan To Kagaku Ryoho; 1992 Dec; 19(14):2338-43. PubMed ID: 1463339 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of hormonally unresponsive prostatic carcinoma. deKernion JB; Lindner A Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779 [TBL] [Abstract][Full Text] [Related]
6. [Results of considerations on the chemotherapy of pancreatic neoplasms]. Klapdor R Med Welt; 1980 Dec; 31(51-52):1853-8. PubMed ID: 6450865 [No Abstract] [Full Text] [Related]
7. Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas. Bukowski RM; Abderhalden RT; Hewlett JS; Weick JK; Groppe CW Cancer Clin Trials; 1980; 3(4):321-4. PubMed ID: 6448716 [TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with 5-FU 1-(aminomethyl)-3-(2-chloroethyl)-3-nitrosourea (ACNU), and mitomycin (FUM) for carcinoma of the pancreas. Meguro S; Kuraishi Y; Ichiba K; Abe M; Yoda T; Mikouchi S Cancer Treat Rep; 1982 Aug; 66(8):1645-6. PubMed ID: 6955023 [No Abstract] [Full Text] [Related]
9. [Effect of cancer chemotherapy for unresectable cancer of the pancreas]. Kinami Y; Konishi K; Shinmura K; Takada M; Sakuma H; Nagakawa T; Miyazaki I Nihon Gan Chiryo Gakkai Shi; 1982 Oct; 17(7):1835-40. PubMed ID: 6819330 [No Abstract] [Full Text] [Related]
10. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051 [TBL] [Abstract][Full Text] [Related]
11. [Analysis of factors affecting clinical cancer chemotherapy]. Wakui A; Taguchi T Gan No Rinsho; 1983 Aug; 29(10):1199-204. PubMed ID: 6415312 [TBL] [Abstract][Full Text] [Related]
12. Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas. Horton J; Gelber RD; Engstrom P; Falkson G; Moertel C; Brodovsky H; Douglass H Cancer Treat Rep; 1981; 65(1-2):65-8. PubMed ID: 6452948 [TBL] [Abstract][Full Text] [Related]
13. [Possibilities and value of intracavitary and systemic chemotherapy of bladder cancer]. Hofmann W; Langkopf B Z Urol Nephrol; 1982 Dec; 75(12):889-95. PubMed ID: 6819737 [No Abstract] [Full Text] [Related]
14. [Chemotherapy of stomach cancer]. Gropp C; Havemann K Z Gastroenterol; 1982 Dec; 20(12):703-9. PubMed ID: 6819730 [TBL] [Abstract][Full Text] [Related]